title: Effects of nasal or pulmonary delivered treatments with an adenovirus vectored interferon (mDEF201) on respiratory and systemic infections in mice caused by cowpox and vaccinia viruses.
abstract: An adenovirus 5 vector encoding for mouse interferon alpha, subtype 5 (mDEF201) was evaluated for efficacy against lethal cowpox (Brighton strain) and vaccinia (WR strain) virus respiratory and systemic infections in mice. Two routes of mDEF201 administration were used, nasal sinus (5-µl) and pulmonary (50-µl), to compare differences in efficacy, since the preferred treatment of humans would be in a relatively small volume delivered intranasally. Lower respiratory infections (LRI), upper respiratory infections (URI), and systemic infections were induced by 50-µl intranasal, 10-µl intranasal, and 100-µl intraperitoneal virus challenges, respectively. mDEF201 treatments were given prophylactically either 24 h (short term) or 56d (long-term) prior to virus challenge. Single nasal sinus treatments of 10(6) and 10(7) PFU/mouse of mDEF201 protected all mice from vaccinia-induced LRI mortality (comparable to published studies with pulmonary delivered mDEF201). Systemic vaccinia infections responded significantly better to nasal sinus delivered mDEF201 than to pulmonary treatments. Cowpox LRI infections responded to 10(7) mDEF201 treatments, but a 10(6) dose was only weakly protective. Cowpox URI infections were equally treatable by nasal sinus and pulmonary delivered mDEF201 at 10(7) PFU/mouse. Dose-responsive prophylaxis with mDEF201, given one time only 56 d prior to initiating a vaccinia virus LRI infection, was 100% protective from 10(5) to 10(7) PFU/mouse. Improvements in lung hemorrhage score and lung weight were evident, as were decreases in liver, lung, and spleen virus titers. Thus, mDEF201 was able to treat different vaccinia and cowpox virus infections using both nasal sinus and pulmonary treatment regimens, supporting its development for humans.
authors.affiliation: Department of Animal, Dairy and Veterinary Sciences, Institute for Antiviral Research, Utah State University, Logan, Utah, United States of America. don.smee@usu.edu
authors.forename: Donald F
authors.initials: DF
authors.lastname: Smee
authors.forename: Min-Hui
authors.initials: MH
authors.lastname: Wong
authors.forename: Brett L
authors.initials: BL
authors.lastname: Hurst
authors.forename: Jane
authors.initials: J
authors.lastname: Ennis
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Turner
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000281:Administration, Intranasal; D000818:Animals; D015605:Cowpox / Q000401:mortality / Q000517:prevention & control*; D015608:Cowpox virus / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics*; D006801:Humans; D007274:Injections, Intraperitoneal; D007372:Interferons / Q000235:genetics*; D051379:Mice; D014615:Vaccinia / Q000401:mortality / Q000517:prevention & control*; D014616:Vaccinia virus / Q000276:immunology*
chemical_list: D007372:Interferons